Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)

Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study

(2015) F. Behrens et al.   JOURNAL OF RHEUMATOLOGY

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

(2014) Christopher Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Updated Guidelines for the Management of Axial Disease in Psoriatic Arthritis

(2014) P. Nash et al.   JOURNAL OF RHEUMATOLOGY

Psoriatic arthritis: current therapy and future approaches

(2014) D. Huynh et al.   RHEUMATOLOGY

Prevalence of psoriatic arthritis in psoriasis patients according to newer classification criteria

(2013) Maldonado Ficco Hernán et al.   CLINICAL RHEUMATOLOGY

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

(2013) Iain B McInnes et al.   LANCET

Inflammatory pathways in spondyloarthritis

(2013) Hulda S. Hreggvidsdottir et al.   MOLECULAR IMMUNOLOGY

Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?

(2010) L. Eder et al.   ANNALS OF THE RHEUMATIC DISEASES

Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci

(2010) John D Reveille et al.   NATURE GENETICS

Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis

(2008) C Lukas et al.   ANNALS OF THE RHEUMATIC DISEASES